Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2009

View Archived Issues

Novel antibacterial agents presented by the University of Notre Dame

Kyowa Hakko Kirin claims new pyridine derivatives for the treatment of dermatologic conditions

SCH-900518 monotherapy or combined with peginterferon shows potential in HCV-infected patients

Litenimod safe in ongoing phase I study in patients with neoplastic meningitis

Tadalafil improves erectile dysfunction in patients with benign prostatic hyperplasia

Some improvements seen with pregabalin in chronic prostatitis/chronic pelvic pain syndrome

Xencor's XmAb Fc-engineered humanized antibodies display increased in vivo antitumor activity

Ipsogen licenses its JAK2 molecular diagnostic assays to ARUP

Alseres and BioAxone make second amendment to 2006 license agreement for Cethrin

FDA grants orphan drug designation to Axentis Pharma's Fluidosomes-tobramycin

Acadia and Biovail enter collaboration for pimavanserin in North America

GR agonist BOL-303242-X shows efficacy in preclinical studies in CNV and postsurgical scarring

Prostanoid agonist PF-04475270 shows promise for glaucoma and ocular hypertension therapy in vivo

MDX-1338 developed for treatment of myeloid and lymphoblastic leukemia; preclinical data presented

Novel allosteric modulators of nicotinic alpha7 receptors reported by Roche

Novel inhibitors of voltage-gated sodium channels described by Vertex as analgesics

Merck KGaA describes new glucokinase activators for prevention and treatment of diabetes

AMDL signs customer agreement with PDL to offer DR-70 cancer test in the U.S.

Avexa and Tibotec sign worldwide exclusive option agreement for HIV-1 integrase program

Bayer and Regeneron extend their global development program for VEGF Trap-Eye

Amylin and Lilly to develop diabetes pen device for once-weekly exenatide

Gen-Probe and DiagnoCure amend license agreement for PCA3-based prostate cancer tests

NICE issues preliminary positive recommendations for Basilea's eczema drug Toctino

Ranbaxy initiates phase III clinical trials for new antimalarial molecule

Pharmaxis reports positive results from phase III clinical trial of Bronchitol in CF

Fovea reports results from clinical trial of Prednisporin in allergic conjunctivitis

FDA Advisory Committee set to review Arzerra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...